StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS - Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright reissued a "buy" rating and issued a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Up 23.2 %

Shares of NYSE SENS traded up $0.11 during mid-day trading on Thursday, reaching $0.59. 19,109,396 shares of the company's stock were exchanged, compared to its average volume of 3,794,680. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The business has a fifty day simple moving average of $0.35 and a 200 day simple moving average of $0.38. Senseonics has a twelve month low of $0.25 and a twelve month high of $0.75. The firm has a market capitalization of $348.86 million, a price-to-earnings ratio of -4.51 and a beta of 0.77.

Insider Buying and Selling

In other Senseonics news, CEO Timothy T. Goodnow purchased 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the business's stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now owns 2,478,844 shares of the company's stock, valued at approximately $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Senseonics

Large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC lifted its position in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock worth $166,000 after acquiring an additional 85,501 shares during the last quarter. FMR LLC increased its stake in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after acquiring an additional 167,970 shares during the last quarter. Geode Capital Management LLC raised its position in Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock valued at $2,042,000 after purchasing an additional 179,103 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Senseonics during the third quarter worth $117,000. Finally, Symmetry Partners LLC acquired a new stake in shares of Senseonics in the 3rd quarter valued at $164,000. Institutional investors own 12.36% of the company's stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.